



# MOLECULAR TARGETS PLATFORM (MTP)

User Guide

07/24/2023

## Version History

Version	Date	Description	Author
1.0.0	08/04/2022	Initial Release	MTP Team
1.1.0	12/12/2022	Data update release	MTP Team
2.0.0	06/02/2023	Data and widget update release	MTP Team
2.1.0	07/24/2023	Plot Generation Improvement	MTP Team

## Table of Contents

Introduction, Overview and Main Landing Page.....	3
Pediatric Cancer Data Navigation Page from the Home Page.....	4
Searching.....	4
Evidence Pages.....	5
General Widget Views.....	5
Somatic Alteration Views.....	6
Gene Expression Views.....	7
Epigenetic Modification Views.....	8
Differential Expression Views.....	9
OT Search Page.....	10
Association Profiles and Heatmaps.....	10
About Molecular Targets.....	11
About Molecular Targets.....	11
Latest Release.....	11
Change Log.....	12
GraphQL API.....	12
User Guide.....	13
FDA Pediatric Molecular Target Lists.....	13
Step-by-Step guidance on how an investigator might use MTP.....	14

## Introduction and Overview

The Molecular Targets Platform (MTP) is being developed as an instance of the widely known and respected EMBL [Open Targets](#) platform as a part of the National Cancer Institute's (NCI) [Childhood Cancer Data Initiative](#) (CCDI). This initiative is tasked with building a set of tools and resources centered around childhood cancer research and patient care. We believe that through enhanced data sharing, we can improve our understanding of cancer biology so that new preventative measures and treatments may be uncovered. Our goal is to ensure that researchers learn from every child with cancer in order to extend the survivorship and quality of life for children with pediatric cancers.

Specifically, MTP is a collaborative effort between the Children's Hospital of Philadelphia ([CHOP](#)) and the Frederick National laboratory ([FNL](#)) with input from the National Cancer Institute ([NCI](#)) and Food Drug Administration ([FDA](#)). The MTP, a searchable graphical user interface, is being developed to allow systematic drug-target identification and prioritization based on existing evidence to ultimately impact childhood cancer treatment. The initial goal of MTP is to integrate FDA's RMTL ([Relevant Molecular Target List](#)) with pre-clinical and clinical pediatric cancer datasets having somatic alteration data (SNVs, CNVs and gene fusions) and gene expression data. Open Targets native data is also present within MTP. Our integration of [GTEx](#) data enables comparisons of Pediatric versus Adult data. Our use of common ontological hierarchies has aided in harmonizing disease, gene (target) and agent (drug) terms. A few examples of pediatric data resources that have been added to MTP are TARGET, KidsFirst, and OpenPedCan. Other data resources, such as PIVOT, will be added in subsequent releases.

This document describes a high-level view of the features and functionalities within MTP. Investigators are encouraged to explore MTP for themselves using this guide as a primer.

## Main Landing Page

The main MTP landing page is where users can navigate to the one of several sites, namely: the FDA PMTL Page, an About Page and the Pediatric Cancer Data Navigation Page. Note: RMTL (Relevant Molecular Target List) has been renamed to PMTL (Pediatric Molecular Target List).




Figure 1: MTP Home Page

## Pediatric Cancer Data Navigation Page

Users can find specific pediatric cancer data by clicking the link in the main page menu bar or the title bar to get to the Pediatric Cancer Data Navigation Page.




Figure 2: Accessing the Pediatric Cancer Data Navigation Page

On the Pediatric Cancer Data Navigation Search Page, users can query a Gene (target) and/or Disease by selecting their entry from the drop-down list and clicking “Search”.




Figure 3: Performing a search on the Pediatric Cancer Data Navigation Page

Users view the returned search results on the Evidence page. The summary display allows the user to quickly assess which diseases have data for a given data type, indicated by the green checkmarks. Note: the presence of a green checkmark only indicates that data is present but does not indicate whether the data is normal or abnormal. This figure shows the results returned when searching for PTEN. Next, the desired Evidence Page for a particular disease can be displayed by clicking on the “Evidence Page”. Links are also provided for overview information about the gene and disease as well.

**Pediatric Cancer Data Navigation**

Search for a **Target**, **Disease**, or **both** to navigate our dataset containing **43,880 Targets** and **41 Diseases** across **1,446,573 Evidence Pages**.

Gene Symbol:  Disease:

In the resulting table:

- Each **Evidence** page link opens a page presenting all available data within the Molecular Targets Platform including available pediatric cancer data associating the specific target with the specific disease
- Each **Gene symbol** page link opens a page presenting all available data within the Molecular Targets Platform including available pediatric cancer data for the specific target
- Disease** pages linked in this table will not contain pediatric data
- Refining a search will query the entire database
- A maximum of 10,000 results are returned in the search results

Found **36 Diseases** with **PTEN** pediatric cancer evidence data. Note that the existence of data does not necessarily indicate significance.

Gene symbol	Disease	Evidence	SNV	CNV	Fusion	Gene Expression
PTEN	Ewing sarcoma	<a href="#">Evidence Page</a>		✓		✓
PTEN	acute lymphoblastic leukemia	<a href="#">Evidence Page</a>	✓		✓	✓
PTEN	acute myeloid leukemia	<a href="#">Evidence Page</a>	✓		✓	✓

Figure 4: Results returned from a search on the Pediatric Cancer Data Navigation Page

Here, the evidence for ALK in Ganglioneuroblastoma was chosen. Now the user can see the specific data types that are available within “widgets”. Blue widgets are native to Open Targets while green widgets represent pediatric data that has been added and does not exist within native Open Targets. Gray widgets have no data.

**Evidence for ALK in ganglioneuroblastoma**

**ALK** FDA PML: Relevant Molecular Target

**ganglioneuroblastoma**

**OpenPedCan Somatic Alterations** (SA) Available

**OpenPedCan Gene Expression** (GX) Available

**Epigenetic Modification** (EM) Available

**OT Genetics Portal** (OT) no data

**ClinVar** (CV) no data

**Gene Burden** (GB) no data

**UniProt variants** (UV) no data

**ClinGen** (CG) no data

**Orphanet** (OR) no data

**CHEMBL** (CH) no data

**Project Score** (PS) no data

**Cancer Biomarkers** (CB) no data

**SLAPenrich** (SL) no data

**PROSeq** (PR) no data

**Reactive** (RE) no data

**Gene signatures** (GS) no data

**Europe PMC** (EP) 15 entries

**Expression Atlas** (EA) no data

Figure 5: General Widget view of the returned Evidence for a given gene and disease  
The user can click on the Somatic Alterations widget in this example BRAF in Osteosarcoma.




Figure 6: Somatic Alteration Widget View

Next, the user will see multiple tabs: SNV by Gene, SNV by Variant, CNV by Gene, Fusion by Gene and Fusion. Clicking on any tab shows the corresponding data, along with many useful columns such as frequency of a somatic alteration in the dataset and, in some cases, links to PedcBioPortal information. Active tabs are colored green. If a tab is not highlighted, there is no data for that data type. Some columns are filterable. If a gene is on the PMTL list, it is indicated by a blue circle with a white “R” inside. The data is downloadable in json and tsv formats and by API query.





Figure 7: Table indicating Data Types within the Somatic Alteration Widget

The user can click on the Gene Expression Widget.



*Figure 8: Gene Expression Widget*

Next, the user will see choices between Linear and Log10 views of the graph of PTEN expression in Acute Lymphoblastic Leukemia versus the expression of GTEx normal tissue. The data is downloadable in json and tsv formats.



Figure 9: Gene Expression Widget view with graphical display choice tabs



The user can click on the Epigenetic Modification Widget.

The screenshot shows the 'Evidence for FLT3 in glioma' page on the Molecular Targets Platform. The page features a sidebar with navigation icons (SA, GX, EM, etc.) and a main content area. The 'Epigenetic Modification' widget is highlighted with a red box. Below the widget, there are several data sources listed, including OpenPedCan Somatic Alterations, OpenPedCan Gene Expression, and various genetic association studies. The 'Epigenetic Modification' widget is currently set to 'Available'.

Figure 10 : Epigenetic Modification Widget

Next, the user will see choices for viewing either Methylation by Gene or Methylation by Isoform data. The data is downloadable in json and tsv formats. An API query is available as well.

The screenshot shows the 'Epigenetic Modification' widget view. It displays a table of methylation data associated with FLT3 in pediatric glioma. The table has columns for Gene symbol, Gene Feature, Dataset, Disease, RNA Correlation, Median TPM, Probe ID, Chromosome, Location, Beta-value, and Beta-value Quantile. The 'Methylation by Gene' tab is selected, and the 'Methylation by Isoform' tab is also visible. Below the table, there are download choice tabs for JSON, TSV, and API query. The table data is as follows:

Gene symbol	Gene Feature	Dataset	Disease	RNA Correlation	Median TPM	Probe ID	Chromosome	Location	Beta-value	Beta-value	Beta-value	Beta-value	Beta-value
									Quantile 1	Quantile 2	Quantile 3	Quantile 4	Quantile 5
FLT3	intron	PBTA	High-grade glioma	0.04084071138666	0.08	cg23248781	chr13	28059293	0.474585508348578	0.8551852965878	0.876968283545481	0.887633922706651	0.82594
FLT3	exon	PBTA	Subependymal Giant Cell Astrocytoma	-0.82604635562546	0.095	cg15613534	chr13	28049444	0.61330873777329	0.669136027620651	0.73227587751295	0.833196368821753	0.873331
FLT3	intron	PBTA	Low-grade glioma	0.259749778390886	0.18	cg23816260	chr13	28041781	0.050613166006785	0.398093821041023	0.560288849127979	0.721730183388839	0.906181
FLT3	intron	PBTA	Schwannoma	0.102702591289095	0.21	cg20574757	chr13	28016104	0.50474232608115	0.7393114003251	0.8489972878406	0.872973742650005	0.915831
FLT3	promoter	PBTA	Diffuse midline glioma	-0.0527532620431797	0.085	cg24454143	chr13	28101128	0.0469702843155993	0.0765347499104567	0.0938895725423693	0.12092208737762	0.439791
FLT3	intron	PBTA	Diffuse hemispheric glioma	-0.0459182131376073	0.05	cg15456502	chr13	28016934	0.0425588256274853	0.140408890759494	0.161846205899044	0.267866898986038	0.522110
FLT3	exon	PBTA	Diffuse midline glioma	0.0450919849121639	0.085	cg15613534	chr13	28049444	0.124310223641825	0.339775405770206	0.515896917590455	0.700779758865666	0.844631
FLT3	intron	PBTA	Schwannoma	-0.130156130573331	0.21	cg16613691	chr13	28023090	0.0689195572587391	0.0923913307020513	0.153715157519999	0.2071160819136	0.316241
FLT3	intron	PBTA	Diffuse intrinsic pontine glioma	1	1.476	cg22915974	chr13	28015408	0.836278877938925	0.860236862168359	0.884194846397793	0.908152830627327	0.932110
FLT3	exon	PBTA	Pilocytic astrocytoma	NA	NA	cg15126273	chr13	28003908	0.528476232752537	0.528476232752537	0.528476232752537	0.528476232752537	0.528471

Figure 11: Epigenetic Modification Widget view with table display choice tabs

The user can view a non-batch corrected Differential Expression heatmap in a Gene Page (ex. KRAS), where one gene in all Pediatric diseases vs all GTex Tissue is displayed.



Figure 12: Differential Expression heatmap Widget – Gene page view

The user can also view a non-batch corrected Differential Expression heatmap in a Disease Page (ex. Ependymoma), where top differentially expressed genes in one disease are compared to GTex tissue. The sorting feature allows users to select how they prefer to rank-order the data.




Figure 13: Differential Expression heatmap Widget – Disease page view

## Open Targets Data Search Page

At any time, the user can navigate back to the main landing page by clicking on the persistent title at the top left of the screen. Diseases, targets, and drugs can be searched on this main page. Open Targets data will be displayed in the resulting screens. The native Open Targets data is mostly adult data. (Note: To see the added Pediatric datasets, this page provides two links to the Pediatric Cancer Data Navigation page for a view of the Pediatric data, as mentioned above in Figure 2).




Figure 14: Open Targets Search page

When searching by a gene (aka Target), the user can see two tabs presented. The “Associated Disease” tab shows all diseases ranked by descending evidence (highest ranking at the top) in a heatmap. The heatmap also shows what kind of data led to the score as well as an overall association score. The view allows searching by a specific gene in the search bar above and to the left of the heatmap. Alternately, one can begin by searching for a specific disease and an Associated genes heatmap are displayed.




Figure 15: Open Targets Search page

## About Molecular Targets Page

The About Page can be navigated to from the main landing page and has five pull-down choices. The choice of “About Molecular Target” will display a page with broad sections describing the derivation of the platform, Pediatric Cancer Diseases, Pediatric Cancer Data Sources, Data Processing methods and Pediatric Cancer Data Visualizations as well as other information.




Figure 16: About Page content

The choice of “Latest Release” will provide information about data and feature in a new release.




Figure 17: About Page → “Latest Release” page

The “Change Log” will provide the user with each version of a particular MTP release.

**Change Log**

The Molecular Targets Platform integrates many different sources of data and analyses, all of which are updated at varying intervals. In order to comprehensively track changes, the various changelogs are aggregated here.

<b>Open Targets Platform</b> Version in use: 22.11 (Released 2022-11-24) <a href="#">Detailed Change Log: Open Targets Platform</a>	The Open Targets Platform version represents the built-in data and functions of the Molecular Targets Platform. This includes all data, displays, and site behavior not otherwise defined in this About page.
<b>Molecular Targets Platform Frontend</b> Version in use: v2.0.0 <a href="#">Detailed Change Log: MTP Frontend Release</a>	The Molecular Targets Platform Frontend contains all of the visual and user-focused components of the site.
<b>Molecular Targets Platform Backend</b> Version in use: v2.0.1_L22_1_Lchq_22 <a href="#">Detailed Change Log: MTP Backend Release</a>	The Molecular Targets Platform Backend contains all of the database and infrastructure components of the site.
<b>OpenPedCan Analyses</b> Version in use: SomaticAlterations_v111, GeneExpression_v10 <a href="#">Detailed Change Log: OpenPedCan Analysis Release</a>	The OpenPedCan version represents new analysis results used in the OpenPedCan Somatic Alterations and Gene Expression displays.
<b>OncoKB Cancer Gene List</b> Version in use: v3.5 (Released 2021-07-16) <a href="#">Detailed Change Log: OncoKB Release</a>	The OncoKB Cancer Gene List version represents the genes identified as OncoKB oncogenes or tumor suppressor genes within the OpenPedCan Somatic Alterations display.
<b>FDA Pediatric Molecular Target Lists</b> Version in use: v1.1 (Released 2023-03-10) <a href="#">Detailed Change Log: MTP PMTL Documentation</a>	The FDA PMTL version represents the computable interpretation of the lists as used within the Molecular Targets Platform. When the FDA publishes new lists, new computable interpretations will be updated here.

**National Cancer Institute**  
at the National Institutes of Health

**CONTACT INFORMATION**  
Contact Us

**NIH POLICIES**  
Policies  
Disclaimer  
Accessibility  
FOIA  
HHS Vulnerability Disclosure

**MORE INFORMATION**  
About MTP

12 version: v2.0.0  
10 version: v2.0.0 (2022-11-24)  
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

Figure 18: About Page --> Change Log content

The “GraphQL API” will allow the user to query a single entity or target-disease association.

**API**

The Molecular Targets Platform is powered by a GraphQL API that supports graphical queries for a single entity or target-disease association across our knowledge graph. Please note that our API is optimised for a

**Example queries**

- Target-disease association
- Target-disease evidence
- Target annotation
- Disease annotation
- Drug annotation

**1**

```
{
  "syntaxError": "Syntax error while parsing ExecutableDefinition or TypeSystemDefinition",
  "locations": [
    {
      "line": 1,
      "column": 1
    }
  ]
}
```

**QUERY VARIABLES** **REQUEST HEADERS**

Figure 19: About Page → GraphQL API query

The “User Guide” will provide information about the features of the MTP website along with a link to download a pdf version of the guide.




Figure 20: About Page → User Guide page

## FDA Pediatric Molecular Targets Page

The Pediatric Molecular Targets (PMTL) page provides links to the FDA documentation and displays all the Relevant Molecular Targets with corresponding FDA-derived information in sortable columns. The PMTL list is exportable in json, tsv and csv formats.

US Food & Drug Administration Pediatric Molecular Target Lists (FDA PMTL)				
Version 1.1				
Targets in the FDA's Pediatric Molecular Target Lists (PMTL) are important for studies of pediatric cancer and have special legal requirements associated with drug development. The table below is a computable interpretation of the target lists published by the FDA. See our <a href="#">FDA PMTL Documentation</a> or the official <a href="#">FDA publication</a> for details.				
Each target in the list is designated as either a <span style="color: blue;">●</span> <b>Relevant Molecular Target</b> or <span style="color: grey;">●</span> <b>Non-Relevant Molecular Target</b> . Any target not in this list is considered an <span style="color: grey;">●</span> <b>Unspecified Target</b> by default.				
Columns Description				
Target Symbol	Designation	FDA Class	FDA Target	Mapping Description
Search...	Select...	Select...	Search...	Select...
ABL1	<span style="color: blue;">●</span> Relevant Molecular Target	Gene Abnormality	ABL1/2   Gene Abnormality: ABL1/2 gene fusions (BCR-ABL1, etc.)	Separate list
ABL2	<span style="color: blue;">●</span> Relevant Molecular Target	Gene Abnormality	ABL1/2   Gene Abnormality: ABL1/2 gene fusions (BCR-ABL1, etc.)	Separate list
BCR	<span style="color: blue;">●</span> Relevant Molecular Target	Gene Abnormality	ABL1/2   Gene Abnormality: ABL1/2 gene fusions (BCR-ABL1, etc.)	Separate gene fusion
ACVR1	<span style="color: blue;">●</span> Relevant Molecular Target	Gene Abnormality	ACVR1   Gene Abnormality: ACVR1	Unchanged from FDA lists
ALK	<span style="color: blue;">●</span> Relevant Molecular Target	Gene Abnormality	ALK   Gene Abnormality: ALK and ALK gene fusions	Unchanged from FDA lists
ASCL1	<span style="color: blue;">●</span> Relevant Molecular Target	Gene Abnormality	ASCL1   Gene Abnormality: ASCL1 gene	Unchanged from FDA lists
BRAF	<span style="color: blue;">●</span> Relevant Molecular Target	Gene Abnormality	BRAF   Gene Abnormality: BRAF	Unchanged from FDA lists
BRD3	<span style="color: blue;">●</span> Relevant Molecular Target	Gene Abnormality	BRD3-NUTM1   Gene Abnormality: BRD3-NUTM1	Separate gene fusion
NUTM1	<span style="color: blue;">●</span> Relevant Molecular Target	Gene Abnormality	BRD3-NUTM1   Gene Abnormality: BRD3-NUTM1	Separate gene fusion

Figure 21: FDA Pediatric Molecular Targets Page



## Step-by-Step guidance on how an investigator might use MTP

### Question: What is the landscape of FGFR3 mutations in all pediatric cancers?

- Do mutations exist and are there specific histologies in which they are enriched?
- Can I find out if there are any gene amplifications in any pediatric cancers?
- There is an ongoing debate as to whether this receptor is highly over-expressed at the RNA level. Can I query RNA-seq datasets to look at RNA expression and/or see the data displayed as a Differential Expression heatmap?
- Can I find out whether there are any splice-site variants present in order to see whether a protein-domain specific adult cancer drug might be adapted to pediatric cancer use?
- Are there any epigenetic modifications playing a role in this gene?

### Answers from MTP searching:

- **We can view Somatic Mutations that exist and their frequencies and in what specific histologies they are found:** From the main menu, click on the link for “Pediatric Cancer Data Navigation”. Searching by Gene symbol “FGFR3” returns a list of 36 diseases with pediatric cancer evidence data, 11 of which have SNV data. If, for example, you click the “Evidence Page” link for osteosarcoma, then click on the OpenPedCan Somatic Alterations green widget button, then choose the tab “SNV By Variant”, you will see that there are 2 mutations, both from patients in the TARGET dataset. The tab “SNV by Gene” shows the number of FGFR3 mutations/osteosarcoma total in the dataset, and if available, a link-out is provided for PedcBioPortal data. There is also a tab for fusion data, if present.
- **We can view Gene Amplifications (CNVs):** From the main menu, click on the link for “Pediatric Cancer Data Navigation”. Searching by Gene symbol “FGFR3” returns a list of 36 diseases with pediatric cancer evidence data, 13 of which have Copy Number data. Click on the kidney Wilms tumor Evidence Page, then click on the OpenPedCan Somatic Alterations green widget button, then choose the tab “CNV By Gene” which shows the types of CN alterations in this disease along with the frequency in the overall dataset.
- **We can view Histology-specific RNA expression across all pediatric diseases and also compared to public RNA-seq datasets such as GTEx:** From the main menu, click on the link for “Pediatric Cancer Data Navigation”. Search by Gene symbol “FGFR3”. In this Evidence view, click on the FGFR3 link, then the Profile tab, then the GX (Gene Expression) widget which takes the user to linear and log10 graphs of the RNA expression levels of FGFR3 (Y- axis) across all pediatric cancers (X-axis). Next, going back to the main menu, click on the link for “Pediatric Cancer Data Navigation”. Searching again by Gene symbol “FGFR3” takes you to the results page. Selecting any of the diseases from the “Evidence Page” links will take you to Gene Expression. Click on the Gene Expression widget to see linear and log10 views of RNA Expression of one particular Pediatric tumor histology (highlighted in blue and located on the far left) versus GTEx normal adult tissue. Additionally,

from the evidence page view, click on the FGFR3 Target page, you can view a widget “Differential Expression (DE) and see a heatmap showing FGFR3 in all Pediatric diseases vs all GTex Tissue is displayed, with or without corresponding GE overlaid.

- **We can view Somatic Mutations including Splice-site mutations:** From the main menu, click on the link for “Pediatric Cancer Data Navigation”. Searching by Gene symbol “FGFR3” takes you to a results page. In this view, click on the FGFR3 link, then the Profile tab, then the SM (Somatic Mutations) “SNV by Variant” tab which shows a listing of all specific genomic mutation by Dataset and Disease and frequency observed. Searching by “Splice\_Site” (a choice for the field “Variant classifications”), will return 6 FGFR3 splice-site mutations across various diseases in one particular dataset.
- **We can view if there are any epigenetic modifications playing a role in this gene:** From the main menu, click on the link for “Pediatric Cancer Data Navigation”. Search by Gene symbol “FGFR3”. In this Evidence view, if there is a checkmark in the methylation column, the user can click on the Evidence button which takes you to a list of widgets including one that is titled “Epigenetic Modification”. Clicking on that widget will take you to a table showing either Methylation by Gene data or Methylation by Isoform data.